NorthStar Medical Technologies

Executive Summary

NorthStar Medical Technologies is a privately held radiopharmaceutical company based in Beloit, Wisconsin, pioneering the production of critical medical radioisotopes using non-reactor electron beam accelerator technology. Founded in 2005, the company specializes in manufacturing actinium-225 (Ac-225) and copper-67 (Cu-67) for diagnostic and therapeutic applications in oncology and other serious diseases. NorthStar operates as a contract development and manufacturing organization (CDMO/CMO), offering scalable and environmentally preferred isotope supply to the global market. The company's proprietary technology addresses supply chain vulnerabilities associated with reactor-based production, positioning it as a key player in the growing targeted alpha therapy and theranostics sectors. Currently at a pre-clinical stage, NorthStar is focused on advancing its manufacturing capabilities and establishing partnerships to support clinical development and commercialization of its radioisotope portfolio.

Upcoming Catalysts (preview)

• H2 2026FDA Pre-IND Meeting for Ac-225 Radiopharmaceutical Pipeline60% success
• H1 2026Strategic CDMO Partnership with a Major Pharma70% success
• H2 2026Series B or C Funding Round to Scale Manufacturing65% success